Form 4: Hinge Health President Sells 15,000 Shares Under 10b5-1 Plan

Hinge Health, Inc. President James Pursley reported the sale of 15,000 Class A Common Stock shares at a weighted average price of $48.3967, executed under a Rule 10b5-1 trading plan.

Summary

• James Pursley, President of Hinge Health, Inc. (HNGE), sold 15,000 shares of Class A Common Stock on December 22, 2025.
• The shares were sold at a weighted average price of $48.3967 per share, with prices ranging from $47.785 to $48.74.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Pursley on June 12, 2025.
• Following this transaction, Mr. Pursley beneficially owns 769,778 shares of Class A Common Stock.
• The reported total number of shares beneficially owned reflects a correction to figures previously reported in Forms 4 filed on November 24, 2025, and December 1, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale, which is a common occurrence for executives managing personal finances. The correction of a previous reporting error is an administrative detail. This transaction does not inherently signal a significant positive or negative shift in the company's operational or financial performance.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than an immediate reaction to new information.
• The filing includes a correction to previously reported share counts, demonstrating a commitment to accurate disclosure.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although it is a common practice for executives to diversify personal holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

Industry Context

This insider transaction report is specific to Hinge Health, Inc. and its executive, and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May observe the insider sale as a data point, though a pre-planned sale typically has less impact than an unplanned one. The correction ensures accurate reporting of insider holdings.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider stock sale by the company's President. This type of transaction, executed under a Rule 10b5-1 plan, is common for executives to manage personal finances and diversify holdings and does not inherently signal a change in the company's fundamental outlook. The correction of previously reported share count is an administrative detail. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter the investment thesis.

Keywords

Hinge Health, HNGE, Insider Trading, Form 4, Stock Sale, James Pursley, Rule 10b5-1